President of Akarapong
- Inventiveness (NASDAQ:VAT) said on Monday that it had secured immediate funding of €94.1 million and up to €348 million to fund completion of the Phase III NATiV3 MASH trial and preparation for the potential marketing approval application and marketing of lanifibranor.
- The transaction was led by New Enterprise Associates, BVF Partners LP and Samsara BioCapital, with participation from additional new and existing investors.
- Source: Press release